The DOI matches its Crossref record; 272 of the 272 references it cites were found in a registry or an index.
RNAi-based therapeutics and tumor targeted delivery in cancer
Abstract
Over the past decade, non-coding RNA-based therapeutics have proven as a great potential for the development of targeted therapies for cancer and other diseases. The discovery of the critical function of microRNAs (miRNAs) has generated great excitement in developing miRNA-based therapies. The dysregulation of miRNAs contributes to the pathogenesis of various human diseases and cancers by modulating genes that are involved in critical cellular processes, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, drug resistance, and tumorigenesis. miRNA (miRNA mimic, anti-miRNA/antagomir) and small interfering RNA (siRNA) can inhibit the expression of any cancer-related genes/mRNAs with high specificity through RNA interference (RNAi), thus representing a remarkable therapeutic tool for targeted therapies and precision medicine. siRNA and miRNA-based therapies have entered clinical trials and recently three novel siRNA-based therapeutics were approved by the Food and Drug Administration (FDA), indicating the beginning of a new era of targeted therapeutics. The successful clinical applications of miRNA and siRNA therapeutics rely on safe and effective nanodelivery strategies for targeting tumor cells or tumor microenvironment. For this purpose, promising nanodelivery/nanoparticle-based approaches have been developed using a variety of molecules for systemic administration and improved tumor targeted delivery with reduced side effects. In this review, we present an overview of RNAi-based therapeutics, the major pharmaceutical challenges, and the perspectives for the development of promising delivery systems for clinical translation. We also highlight the passive and active tumor targeting nanodelivery strategies and primarily focus on the current applications of nanoparticle-based delivery formulations for tumor targeted RNAi molecules and their recent advances in clinical trials in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–272 of 272
Formulation Approaches to Short Interfering RNA and MicroRNA: Challenges and Implications
Guzman‐Villanueva, D., El-sherbiny, I. M., Herrera‐Ruiz, D., Vlassov, A. V., & Smyth, H. D. C. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23300 · Cited by 90
Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy
Babu, A., Muralidharan, R., Amreddy, N., Mehta, M., Munshi, A., & Ramesh, R. (2016) · IEEE Transactions on NanoBioscience · doi:10.1109/tnb.2016.2621730 · Cited by 88
Exosomal miR-141 promotes tumor angiogenesis via KLF12 in small cell lung cancer
Mao, S., Lu, Z., Zheng, S., Zhang, H., Zhang, G., Wang, F., Huang, J., Lei, Y., Wang, X., Liu, C., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01680-1 · Cited by 88
Bayraktar, R., Ivan, C., Bayraktar, E., Kanlikilicer, P., Kabil, N. N., Kahraman, N., Mokhlis, H. A., Karakaş, D., Rodriguez‐Aguayo, C., Arslan, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1959 · Cited by 86
Frishberg, Y., Deschênes, G., Groothoff, J. W., Hulton, S., Magen, D., Harambat, J., Hoff, W. V., Lorch, U., Milliner, D. S., Lieske, J. C., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14730920 · Cited by 85
Zhou, Z., Kennell, C., Lee, J., Leung, Y., & Tarapore, P. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.07.016 · Cited by 84
Tang, J., Howard, C. B., Mahler, S. M., Thurecht, K. J., Huang, L., & Xu, Z. P. (2018) · Nanoscale · doi:10.1039/c7nr08644j · Cited by 81
Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside
Qiu, Y., Lam, J. K. W., Leung, S. W. S., & Liang, W. (2016) · Molecules · doi:10.3390/molecules21091249 · Cited by 77
Siahmansouri, H., Somi, M. H., Babaloo, Z., Baradaran, B., Jadidi‐Niaragh, F., Atyabi, F., Mohammadi, H., Ahmadi, M., & Yousefi, M. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12593 · Cited by 76
Chang, Y., Ding, B., Zhang, X., Deng, X., Deng, K., Cheng, Z., Xing, B., Jin, D., Ma, P., & Lin, J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.014 · Cited by 76
Xia, Y., Guo, M., Xu, T., Li, Y., Wang, C., Lin, Z., Zhao, M., & Zhu, B. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s157519 · Cited by 75
Tumor‐Targeting Multifunctional Nanoparticles for siRNA Delivery: Recent Advances in Cancer Therapy
Ku, S. H., Kim, K., Choi, K., Kim, S. H., & Kwon, I. C. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300607 · Cited by 72
Malhotra, M., Sekar, T. V., Ananta, J. S., Devulapally, R., Afjei, R., Babikir, H. A., Paulmurugan, R., & Massoud, T. F. (2018) · Oncotarget · doi:10.18632/oncotarget.25135 · Cited by 71
Qiu, C., Wei, W., Sun, J., Zhang, H., Ding, J., Wang, J., & Zhang, Q. (2016) · Nanoscale · doi:10.1039/c6nr04034a · Cited by 71
Essex, S., Navarro, G., Sabhachandani, P., Chordia, A., Trivedi, M., Movassaghian, S., & Torchilin, V. P. (2014) · Gene Therapy · doi:10.1038/gt.2014.97 · Cited by 70
Role of antibodies in cancer targeting
Attarwala, H. Z. (2010) · Journal of Natural Science Biology and Medicine · doi:10.4103/0976-9668.71675 · Cited by 68
Büyükköroğlu, G., Şenel, B., Başaran, E., Yenilmez, E., & Yazan, Y. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.10.017 · Cited by 65
Ramot, Y., Rotkopf, S., Gabai, R. M., Zorde Khvalevsky, E., Muravnik, S., Marzoli, G. A., Domb, A. J., Shemi, A., & Nyska, A. (2016) · Toxicologic Pathology · doi:10.1177/0192623316645860 · Cited by 64
Targeting of Tumor Endothelium by RGD-Grafted PLGA-Nanoparticles
Danhier, F., Pourcelle, V., Marchand‐Brynaert, J., Jérôme, C., Féron, O., & Véronique Préat, A. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-391860-4.00008-2 · Cited by 62
Non-coding RNAs in cancer diagnosis and therapy
Rasool, M., Malik, A., Zahid, S., Ashraf, M. A. B., Qazi, M. H., Asif, M., Zaheer, A., Arshad, M. A., Raza, A., & Jamal, M. S. (2016) · Non-coding RNA Research · doi:10.1016/j.ncrna.2016.11.001 · Cited by 62
Zheng, X., Zhang, F., Zhao, Y., Zhang, J., Dawulieti, J., Pan, Y., Cui, L., Sun, M., Shao, D., Li, M., et al. (2018) · Theranostics · doi:10.7150/thno.25255 · Cited by 62
Yan, L., Gao, S., Shui, S., Liu, S., Qu, H., Liu, C., & Zheng, L. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.246 · Cited by 62
Calcium phosphate nanoparticles-based systems for siRNA delivery
Xu, X., Li, Z., Zhao, X., Keen, L. J., & Kong, X. (2016) · Regenerative Biomaterials · doi:10.1093/rb/rbw010 · Cited by 61
Central Delivery of Dicer-substrate siRNA: A Direct Application for Pain Research
Doré-Savard, L., Roussy, G., Dansereau, M., Collingwood, M. A., Lennox, K. A., Rose, S. D., Beaudet, N., Behlke, M. A., & Sarret, P. (2008) · Molecular Therapy · doi:10.1038/mt.2008.98 · Cited by 60
Vermeulen, L. M. P., Brans, T., Smedt, S. C. D., Remaut, K., & Braeckmans, K. (2018) · Nano Today · doi:10.1016/j.nantod.2018.06.007 · Cited by 59
RNA therapeutics: Identification of novel targets leading to drug discovery
Qadir, M. I., Bukhat, S., Rasul, S., Manzoor, H., & Manzoor, M. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29364 · Cited by 57
RNA Biology Provides New Therapeutic Targets for Human Disease
Harries, L. W. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00205 · Cited by 54
Yalçın, E., Kara, G., Çelik, E., Pınarlı, F. A., Saylam, G., Sucularlı, C., Öztürk, S., Yılmaz, E., Bayır, Ö., Korkmaz, M. H., et al. (2019) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2019.1599395 · Cited by 54
Self-citationNing, B., Yu, D., & Yu, A. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113638 · Cited by 54
Moretti, R. M., Marelli, M. M., Groeninghen, J. C. V., & Limonta, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.8.3791 · Cited by 53
Cervantes, A. M. R., Alsina, M., Tabernero, J. M., Infante, J. R., LoRusso, P. M., Shapiro, G. I., Paz-Ares, L. G., Falzone, R., Hill, J., Cehelsky, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3025 · Cited by 53
Titze-de-Almeida, S. S., Brandão, P. R. D. P., Faber, I., & Titze‐de‐Almeida, R. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00434-w · Cited by 52
Lin, X., Qiu, W., Xiao, Y., Ma, J., Xu, F., Zhang, K., Gao, Y., Chen, Q., Li, Y., Li, H., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2019.01397 · Cited by 52
ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer
Görür, A., Bayraktar, R., Ivan, C., Mokhlis, H. A., Bayraktar, E., Kahraman, N., Karakaş, D., Karamil, S., Kabil, N. N., Kanlikilicer, P., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.01.016 · Cited by 52
Rengaswamy, V., Zimmer, D., Süss, R., & Rössler, J. K. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.063 · Cited by 50
Targeted Delivery of miRNA-204-5p By PEGylated Polymer Nanoparticles for Colon Cancer Therapy
Zheng, B. J., Chen, L., Pan, C.-C., Wang, J., Lu, G., Yang, S., Xue, Z., Wang, F., & Xu, C. (2018) · Nanomedicine · doi:10.2217/nnm-2017-0345 · Cited by 50
Tambe, P., Kumar, P., Karpe, Y. A., Paknikar, K. M., & Gajbhiye, V. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b11024 · Cited by 49
Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments
To, K. K. W., Fong, W., Tong, C. W. S., Wu, M.-X., Yan, W., & Cho, W. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1690449 · Cited by 49
Bircan, A., Gürbüz, N., Pataer, A., Caner, A., Kahraman, N., Bayraktar, E., Bayraktar, R., Erdoğan, M. A., Kabil, N. N., & Özpolat, B. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.027 · Cited by 46
miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma
Fuertes, T., Ramiro, A. R., & de Yébenes, V. G. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.08.006 · Cited by 46
Regulation of microvascular permeability by vascular endothelial growth factors
Bates, D. O., Hillman, N. J., Pocock, T., & Neal, C. R. (2002) · Journal of Anatomy · doi:10.1046/j.1469-7580.2002.00047_19.x · Cited by 46
Xie, Y., Killinger, B. A., Moszczyńska, A., & Merkel, O. M. (2016) · Molecules · doi:10.3390/molecules21101334 · Cited by 45
Cationic micelle-based siRNA delivery for efficient colon cancer gene therapy
Lu, Y., Zhong, L., Jiang, Z., Pan, H., Zhang, Y., Zhu, G., Bai, L., Tong, R., Shi, J., & Duan, X. (2019) · Nanoscale Research Letters · doi:10.1186/s11671-019-2985-z · Cited by 44
LH-RH receptors in the human pancreas
Friess, H., Büchler, M. W., Kiesel, L., Krüger, M., & Beger, H. G. (1991) · International Journal of Pancreatology · doi:10.1007/bf02924118 · Cited by 43
Eivazy, P., Atyabi, F., Jadidi‐Niaragh, F., Maleki, L. A., Miahipour, A., Abdolalizadeh, J., & Yousefi, M. (2016) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2016.1185727 · Cited by 43
Martins, G. O., Petrônio, M. S., Lima, A. M. F., Martinez, A. M., Tiera, V. A. D. O., Calmon, M. F., Vilamaior, P. S. L., Han, S. W., & Tiera, M. J. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.03.098 · Cited by 43
Bakan, F., Kara, G., Çakmak, M. Ç., Cokol, M., & Denkbaş, E. B. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.06.028 · Cited by 42
Self-citationControlling miRNA-like off-target effects of an siRNA with nucleobase modifications
Suter, S. R., Ball‐Jones, A. A., Mumbleau, M. M., Valenzuela, R., Ibarra‐Soza, J. M., Owens, H., Fisher, A. J., & Beal, P. A. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02654d · Cited by 42
Milani, R., Brognara, E., Fabbri, E., Manicardi, A., Corradini, R., Finotti, A., Gasparello, J., Borgatti, M., Cosenza, L. C., Lampronti, I., et al. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4810 · Cited by 42
The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers
Mokhlis, H. A., Bayraktar, R., Kabil, N. N., Caner, A., Kahraman, N., Rodriguez‐Aguayo, C., Zambalde, É. P., Sheng, J., Karagoz, K., Kanlikilicer, P., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.019 · Cited by 38
Peptide- and polymer-based delivery of therapeutic RNA
Fröhlich, T., & Wagner, E. (2009) · Soft Matter · doi:10.1039/b916053a · Cited by 37
Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line
Yu, X., Song, Y., Yang, D., He, H., Fu, D., & Jin, C. (2016) · Scientific Reports · doi:10.1038/srep31539 · Cited by 35
Parvani, J. G., & Jackson, M. W. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0482 · Cited by 35
Jiang, Q., Yuan, Y., Gong, Y., Luo, X., Su, X., Hu, X., & Zhu, W. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03051-6 · Cited by 35
Small Delivery Vehicles of siRNA for Enhanced Cancer Targeting
Kim, H. J., Yi, Y., Kim, A., & Miyata, K. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00546 · Cited by 33
Wu, F., Zhang, J., Li, W., Bian, B., Hong, Y., Song, Z., Wang, H.-Y., Cui, F., Li, R., Liu, Q., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18066 · Cited by 30
Schumann, C., Chan, S., Millar, J. A., Bortnyak, Y., Carey, K., Fedchyk, A., Wong, L., Korzun, T., Moses, A. S., Lorenz, A. S., et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.03.005 · Cited by 30
Polyethyleneimine-coated quantum dots for miRNA delivery and its enhanced suppression in HepG2 cells
Liang, G., Li, Y., Feng, W., Wang, X., Jing, A., Li, J., & Kaiwang, M. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s120828 · Cited by 29
Cholic acid-based mixed micelles as siRNA delivery agents for gene therapy
Cunningham, A. J., Gibson, V. P., Banquy, X., Zhu, X. X., & Chain, J. L. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119078 · Cited by 28
Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy
Costa, D. F. G., & Torchilin, V. P. (2018) · Biomedical Microdevices · doi:10.1007/s10544-018-0298-0 · Cited by 27
Recent advances in the targeting of systemically administered non-viral gene delivery systems
Khalil, I. A., Sato, Y., & Harashima, H. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1656196 · Cited by 27
Chitosan Nanoparticles for miRNA Delivery
Denizli, M., Aslan, B., Mangala, L. S., Jiang, D., Rodriguez‐Aguayo, C., Lopez‐Berestein, G., & Sood, A. K. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7138-1_14 · Cited by 26
Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.
Foss, F. M., Querfeld, C., Kim, Y. H., Pinter‐Brown, L. C., William, B. M., Porcu, P., Pacheco, T. R., Haverkos, B. M., DeSimone, J., Guitart, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.2511 · Cited by 26
Exploiting microRNAs As Cancer Therapeutics
Robb, T. J., Reid, G., & Blenkiron, C. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0476-7 · Cited by 25
Kara, G., Parlar, A., Çakmak, M. Ç., Cokol, M., Denkbaş, E. B., & Bakan, F. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111340 · Cited by 25
Self-citationErdoğan, M. A., Ashour, A. A., Yuca, E., Görgülü, K., & Özpolat, B. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.109938 · Cited by 24
A novel multifunctional biomimetic Au@BSA nanocarrier as a potential siRNA theranostic nanoplatform
Wang, Z., Hui, W., Shi, H., Wang, M., Huang, C., & Jia, N. (2016) · Journal of Materials Chemistry B · doi:10.1039/c5tb02326b · Cited by 22
Systemic Delivery of Small Interfering RNA Therapeutics: Obstacles and Advances
Chandela, A., & Ueno, Y. (2019) · Reviews in Agricultural Science · doi:10.7831/ras.7.10 · Cited by 19
Ford, L. P., & Toloue, M. (2010) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.12 · Cited by 11
A new era of treatment for primary hyperoxaluria type 1
Erger, F., & Beck, B. B. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00449-9 · Cited by 10
Cengiz, B. B., Asik, M. D., Kara, G., Türk, M., & Denkbaş, E. B. (2015) · Journal of Nanoparticle Research · doi:10.1007/s11051-015-2980-y · Cited by 8
Self-citationAbstract B32: Silencing of oncogenic KRAS by a mutant-favoring short interfering RNA
Papke, B., Swearingen, A. E. D. V., Feng, A. Y., Azam, S. H., Harrison, E. B., Yang, R. Y., Cox, A. D., Der, C. J., & Pecot, C. V. (2020) · Molecular Cancer Research · doi:10.1158/1557-3125.ras18-b32 · Cited by 2
Cited by
Bai, R., Li, Y., Jian, L., Yang, Y., Zhao, L., & Wei, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01645-2 · Cited by 279
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
The landscape of nanoparticle-based siRNA delivery and therapeutic development
Moazzam, M., Zhang, M., Hussain, A., Yu, X., Huang, J., & Huang, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.005 · Cited by 230
Recent Progress in Extracellular Vesicle-Based Carriers for Targeted Drug Delivery in Cancer Therapy
Tang, Y., Liu, X., Sun, M., Xiong, S., Xiao, N., Li, J., He, X., & Xie, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071902 · Cited by 24
Sharma, S., Bhattacharya, S., Joshi, K., & Singh, S. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05331-8 · Cited by 13
Metadata
- Authors
- Kara, G., Calin, G. A., & Ozpolat, B.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 182
- Pages
- 114113
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W4206527368
- Cited by
- 411
- References
- 272
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.